8-K: Chemed Corporation Lowers 2025 Earnings Guidance Amidst Medicare Cap Limitations and Residential Demand Weakness

Chemed Corporation announced it anticipates lower second quarter earnings and is reducing its full year 2025 guidance due to a projected Medicare Cap revenue limitation for its VITAS subsidiary and unexpected weakness in Roto-Rooter's residential business.

Summary

• Chemed Corporation expects lower second quarter earnings and has reduced its full year 2025 guidance.
• The VITAS subsidiary now projects a Medicare Cap revenue limitation of $18 million to $25 million for its Florida consolidated program for the 2025 government fiscal year ending September 30, 2025.
• This limitation is primarily due to weaker than anticipated Medicare admissions in April and May 2025 in Florida, and a rate differential where the Medicare Cap per admission increased 2.9% while Florida reimbursement increased 5.2%, negatively impacting the calculation by approximately $25 million.
• Previous 2025 guidance did not account for any Florida Medicare Cap.
• Roto-Rooter's residential business experienced unexpected demand weakness in the second quarter of 2025, though commercial demand improved, it was insufficient to offset the residential decline.

Sentiment

Score: 3

Explanation: The announcement indicates a significant negative revision to earnings guidance due to unexpected revenue limitations and demand weakness. While there are positive future mitigation strategies, the immediate financial impact is substantial and negative.

Positives

• VITAS received a Certificate of Need (CON) on June 20, 2025, to begin operating in Pinellas County, Florida, representing a significant growth opportunity and potential for Medicare Cap mitigation in 2026 and beyond.
• Management expects no significant Medicare Cap revenue limitation in Florida for the 2026 fiscal year, assuming the rate differential does not recur, due to new start locations and operational changes.
• Roto-Rooter's commercial demand continued to reflect improved trends in the second quarter of 2025.
• Actual June admissions for VITAS show better trends than projected through the first half of the month.

Negatives

• Anticipated lower second quarter earnings and reduced full year 2025 guidance.
• VITAS projects a Medicare Cap revenue limitation of $18 million to $25 million for its Florida consolidated program for the 2025 Cap Year.
• Weaker than anticipated Medicare admissions in April and May 2025 in Florida contributed to the Medicare Cap issue.
• A rate differential between Medicare Cap per admission increase (2.9%) and Florida reimbursement increase (5.2%) is estimated to negatively impact the Medicare Cap calculation by approximately $25 million.
• Previous 2025 earnings guidance did not include any Florida Medicare Cap.
• Roto-Rooter experienced unexpected weakness in its residential business demand in Q2 2025.

Risks

• Impact of laws and regulations on operations, including Medicare Cap and Medicare reimbursement rates.
• Uncertainty regarding Chemed's estimates of the effect of Medicare Cap on VITAS revenues and future prospects.
• Uncertainties related to VITAS patient mix.
• Uncertainties regarding demand for Roto-Rooter's services.
• The possibility that the rate differential for Medicare Cap calculation could recur for the 2026 Cap Year.
• Actual June results and third-quarter results could significantly impact the current Medicare Cap projection.

Future Outlook

Chemed anticipates lower second quarter earnings and has reduced its full year 2025 guidance. For 2026, management expects no significant Medicare Cap revenue limitation in its Florida consolidated program, assuming the current rate differential does not recur, and sees significant growth opportunities in Pinellas County for VITAS. Roto-Rooter's commercial demand shows improved trends, but residential weakness is a concern.

Management Comments

• In prior public statements, management discussed the possibility that the VITAS subsidiary could have an aggregate Medicare Cap billing limitation (Medicare Cap) related to its Florida consolidated program, excluding Tallahassee.
• Management expects not to have any significant level of Medicare Cap revenue limitation in our Florida consolidated program for the 2026 fiscal year.
• This expectation assumes that the rate differential discussed above does not recur for the 2026 Cap Year. In the event that the rate differential does recur, VITAS will respond with further mitigation strategies at the outset of the 2026 Cap Year.
• Management is in the process of analyzing second quarter performance and the impact of these developments on second quarter results and on full-year 2025 guidance.

Industry Context

The hospice care industry, particularly for Medicare-funded services, is subject to complex regulatory frameworks like the Medicare Cap, which can significantly impact revenue. Fluctuations in admission rates and reimbursement differentials are critical factors. The plumbing and drain cleaning services industry, represented by Roto-Rooter, can be sensitive to residential and commercial demand trends, reflecting broader economic conditions or specific market dynamics.

Comparison to Industry Standards

• Pinellas County's hospice utilization rate is below the state average, indicating an underserved market relative to Florida's overall hospice utilization.
• The Medicare Cap per admission amount increased 2.9% nationally, while VITAS's Florida consolidated program reimbursement increased 5.2%, highlighting a specific rate differential impacting the company.

Stakeholder Impact

• Shareholders: Likely negative impact on share price due to lower earnings guidance and revenue limitations. Increased uncertainty regarding future profitability.
• Employees (VITAS): Potential operational adjustments in Florida programs to mitigate Medicare Cap issues.
• Customers (VITAS): Continued access to hospice care, with potential for expanded services in Pinellas County.
• Customers (Roto-Rooter): No direct impact mentioned, but residential demand weakness could imply market shifts.

Next Steps

• Chemed Corporation will release financial results for the second quarter ended June 30, 2025, on Tuesday, July 29, 2025.
• Chemed will host a conference call and webcast on Wednesday, July 30, 2025, at 10 a.m. ET, to discuss quarterly results and provide a business update.
• Management is analyzing second quarter performance and the impact of developments on results and full-year 2025 guidance.
• VITAS plans to implement further mitigation strategies at the outset of the 2026 Cap Year if the rate differential recurs.
• VITAS will begin operating in Pinellas County, Florida, in 2026 and beyond.

Key Dates

Recommendation

Keywords

Chemed Corporation, CHE, VITAS Healthcare, Roto-Rooter, Earnings Guidance, Medicare Cap, Hospice Care, Financial Results, Q2 2025, Full Year 2025, Revenue Limitation, Pinellas County, Certificate of Need, Residential Business, Plumbing Services, Drain Cleaning, Healthcare Regulation, Financial Outlook